In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...
21h
Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Bimagrumab, a drug originally developed for muscle loss, may help reduce the risk of osteoporosis in weight loss medication ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback